Abcam, ab308290, Anti-VGF antibody [EPR27029-73] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal VGF antibody. Carrier free. Suitable for WB, IHC-P, mIHC and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR27029-73,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:mIHC, WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
VGF also known as non-acronymic VGF is a neuropeptide precursor protein with a molecular mass approximately 68 kDa. It is expressed in neuroendocrine and neuronal tissues including the brain spinal cord and peripheral nervous system. VGF is synthesized as a large precursor and subsequently processed into smaller bioactive peptides with a variety of functions. The distribution and processing of VGF peptides suggest its diverse roles across different physiological contexts.
Biological function summary
VGF-derived peptides exert significant influence on energy balance neurogenesis and synaptic plasticity. These peptides participate in the regulation of appetite and energy expenditure contributing to body weight management. They are also involved in nerve growth and repair mechanisms. VGF peptides act independently or in conjunction with other neuropeptides and factors within the nervous system though it does not form a stable complex with other proteins.
Pathways
Few proteins have as diverse involvement as VGF in the neuroendocrine system's regulation. VGF links to the neurotrophic signaling pathway which promotes neuronal survival and growth. It shows interactions with proteins such as Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) which support cellular health and energy homeostasis. VGF's role assists in the modulation of these pathways facilitating communication between energy state signals and neuronal networks.
Alterations in VGF expression have implications in neurodegenerative diseases and mood disorders. Reduced levels of VGF peptides associate with Alzheimer's disease affecting cognitive functions and synaptic integrity. Additionally VGF influences in mood regulatory pathways relate it to major depressive disorder potentially interacting with proteins like the serotonin transporter which modulates mood and stress responses. Understanding VGF and its pathways can inform therapeutic strategies for these conditions.